Sino Biopharmaceutical Limited Depositary Receipt (SINOBIO19)

Overview

Sino Biopharmaceutical Limited Depositary Receipt represents shares in Sino Biopharmaceutical Limited, an investment holding company that stands as a leading innovation-driven pharmaceutical group in China. The company is dedicated to the research, development, manufacturing, and distribution of modernized Chinese medicines and chemical drugs, effectively covering the entire industry chain supported by a robust sales system. With a strong foothold in significant therapeutic areas such as oncology, hepatology, respiratory diseases, and surgery/analgesia, Sino Biopharmaceutical offers a range of biologics and treatments for various health conditions, including tumors, liver diseases, and diabetes.

As a prominent pharmaceutical entity, the company operates through various segments, including Modernized Chinese Medicines and Chemical Medicines, generating substantial revenue primarily from mainland China. Its operations are bolstered by subsidiaries such as Chia Tai Tianqing Pharmaceutical Group and Beijing Tide Pharmaceutical. Since its listing on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical has become a key constituent of major indices like the Hang Seng Index and MSCI China Index. The firm has established production bases across China, employing over 23,000 individuals, and is globally recognized as one of the top pharmaceutical enterprises, placing significant emphasis on research and development for innovative therapies.

Products and Services

• Modernized Chinese Medicines

  This segment focuses on advancing traditional Chinese medicine through modern scientific techniques, aiming to enhance efficacy and safety for patients. The company develops a variety of products grounded in age-old practices while integrating contemporary research methodologies.

• Chemical Medicines

  Sino Biopharmaceutical manufactures chemical drugs that encompass an array of therapeutic areas. These products are designed based on rigorous research aimed at developing safe and effective treatments for conditions like infections, chronic diseases, and acute medical issues.

• Oncology Products

  With an emphasis on oncology, the company offers a range of biologics and treatments specifically targeted for cancer patients. This includes innovative therapies aimed at tumor management, personalized medicine approaches, and supportive care solutions.

• Hepatology Products

  The hepatology segment provides therapeutics specifically for liver conditions, including treatments for hepatitis and liver cancer. Research in this area ensures the development of advanced medications that contribute to better patient outcomes.

• Respiratory Disease Treatments

  Sino Biopharmaceutical produces several therapies designed for respiratory diseases, focusing on both chronic and acute conditions. These drugs are formulated to improve lung function and enhance the quality of life for those affected.

• Diabetes Management

  Recognizing the growing prevalence of diabetes, the company offers treatments aimed at managing blood sugar levels, addressing both Type 1 and Type 2 diabetes through innovation and patient-centric solutions.

• Surgical and Analgesia Products

  This category encompasses a range of anesthetics and analgesics used in surgical procedures to ensure patient comfort and safety. These products are essential for pain management in both inpatient and outpatient settings.